Moderna initiates phase 3 trial of RSV vaccine candidate
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) has been given the green light by a Data and Safety Monitoring Board to begin the phase 3 trial of its Respiratory Syncytial Virus ("RSV") vaccine candidate, mRNA-1345.
The study, known as ConquerRSV, is expected to enroll ~34K participants ages 60 and older.

The endorsement from the board follows an independent review of phase 2 data.
Read why Seeking Alpha contributor Geoff Considine considers Moderna a hold.